Plasma cetuximab concentrations correlate with survival in patients with advanced KRAS wild type colorectal cancer
Di Maria Jiang,Shruti Parshad,Luna Zhan,Hao-Wen Sim,Lillian L Siu,Geoffrey Liu,Jeremy D Shapiro,Timothy J Price,Derek J Jonker,Christos S Karapetis,Andrew H Strickland,Wenjiang Zhang,Mark Jeffery,Dongsheng Tu,Siobhan Ng,Sabe Sabesan,Jenny Shannon,Amanda Townsend,Chris J O'Callaghan,Eric X Chen,Lillian L. Siu,Jeremy D. Shapiro,Timothy J. Price,Derek J. Jonker,Christos S. Karapetis,Andrew H. Strickland,Chris J. O'Callaghan
DOI: https://doi.org/10.1016/j.clcc.2023.08.006
IF: 4.035
2023-08-25
Clinical Colorectal Cancer
Abstract:Background Cetuximab is a standard of care therapy for patients with RAS wild-type (WT) advanced colorectal cancer. Limited data suggest a wide variation in cetuximab plasma concentrations after standard dosing regimens. We correlated cetuximab plasma concentrations with survival and toxicity. Methods The CO. 20 study randomized patients with RAS WT advanced colorectal cancer in a 1:1 ratio to cetuximab 400 mg/m 2 intravenously followed by weekly maintenance of 250 mg/m 2 , plus brivanib 800 mg orally daily or placebo. Blood samples obtained at week 5 pre-cetuximab treatment were analyzed by ELISA. Patients were grouped into tertiles based on plasma cetuximab concentrations. Cetuximab concentration tertiles were correlated with survival outcomes and toxicity. Patient demographic and biochemical parameters were evaluated as co-variables. Results Week 5 plasma cetuximab concentrations were available for 591 patients (78.8%). The median overall survival (OS) was 11.4 months and 7.8 months for patients in the highest (T3) and lowest tertiles (T1) respectively. On multivariable analysis, plasma cetuximab concentration was associated with OS (HR 0.66, 95% confidence interval (CI): 0.53 – 0.83, p < 0.001, T3 vs T1), and a trend towards progression-free survival (HR 0.82, 95% confidence interval: 0.66 – 1.02, p = 0.07, T3 vs T1). There was no association between cetuximab concentration and skin toxicity or diarrhea. Conclusion The standard cetuximab dosing regimen may not be optimal for all patients. Further pharmacokinetic studies are needed to optimize cetuximab dosing given the potential improvement in overall survival. Micro abstract Cetuximab is a standard of care therapy for patients with RAS wild-type (WT) advanced colorectal cancer. We correlated cetuximab plasma concentrations after 4 weeks of treatment with survival and toxicity. Plasma cetuximab concentration was associated with OS (HR 0.66, 95% confidence interval (CI): 0.53 – 0.83, p < 0.001, T3 vs T1), and a trend towards progression-free survival (HR 0.82, 95% confidence interval: 0.66 – 1.02, p = 0.07, T3 vs T1). There was no association between cetuximab concentration and skin toxicity or diarrhea. The standard cetuximab dosing regimen may not be optimal for all patients.
oncology